Xin Lang Cai Jing·2025-11-27 08:53Core Viewpoint - The announcement indicates that the company has received approval from the National Medical Products Administration for its epinephrine injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Company Developments - The company submitted the application materials in February 2024 and received acceptance, with approval granted in November 2025 [1] - The epinephrine injection is indicated for severe respiratory distress and anaphylactic shock, classified as a Category A drug under medical insurance [1] Group 2: Market Insights - The estimated sales of epinephrine in Chinese public medical institutions is approximately 270 million yuan in 2024 [1] - The successful evaluation is expected to enhance the company's market competitiveness, although drug sales are subject to uncertainties influenced by policies and market conditions [1]